Exact Mass: 303.1987

Exact Mass Matches: 303.1987

Found 290 metabolites which its exact mass value is equals to given mass value 303.1987, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

SCHEMBL4290912

N(6)-[(indol-3-yl)acetyl]-L-lysine

C16H21N3O3 (303.1583)


D006133 - Growth Substances > D010937 - Plant Growth Regulators > D007210 - Indoleacetic Acids

   

alpha-Ethyl-alpha,beta-diphenyl-2-pyridineethanol

alpha-Ethyl-alpha,beta-diphenyl-2-pyridineethanol

C21H21NO (303.1623)


   

Samandarone

2,5-Epoxycyclopenta[5,6]naphth[1,2-d]azepin-9(1H)-one,hexadecahydro-5a,7a-dimethyl-, (2S,5R,5aS,5bS,7aR,10aS,10bS,12aR)-

C19H29NO2 (303.2198)


   

Vildagliptin

(2S)-1-{2-[(3-hydroxyadamantan-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile

C17H25N3O2 (303.1947)


Vildagliptin, previously identified as LAF237, is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucaon release by the alpha cells of the islets of Langerhans in the pancreas. It is currently in clinical trials in the U.S. and has been shown to reduce hyperglycemia in type 2 diabetes mellitus. While the drug is still not approved for use in the US, it was approved in Feb 2008 by European Medicines Agency for use within the EU and is listed on the Australian PBS with certain restrictions. A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1].

   

gamma-Glutamylarginine

(2S)-2-{[(4S)-4-amino-4-carboxy-1-hydroxybutylidene]amino}-5-carbamimidamidopentanoate

C11H21N5O5 (303.1543)


gamma-Glutamylarginine is a dipeptide composed of gamma-glutamate and arginine, and is a proteolytic breakdown product of larger proteins. It belongs to the family of N-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom. gamma-Glutamylarginine is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

Valyltryptophan

(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-(1H-indol-3-yl)propanoic acid

C16H21N3O3 (303.1583)


Valyltryptophan is a dipeptide composed of valine and tryptophan. It is an incomplete breakdown product of protein digestion or protein catabolism. Dipeptides are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Some dipeptides are known to have physiological or cell-signalling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor Dipeptide 2 (N-Valyltryptophan; Val-Trp) is a bioactive peptide with anti-aging effect and has been reported used as a cosmetic ingredient[1].

   

Tryptophyl-Valine

2-{[2-amino-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino}-3-methylbutanoate

C16H21N3O3 (303.1583)


Tryptophyl-Valine is a dipeptide composed of tryptophan and valine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

   

Glutamylarginine

(2S)-2-{[(2S)-2-amino-4-carboxy-1-hydroxybutylidene]amino}-5-carbamimidamidopentanoate

C11H21N5O5 (303.1543)


Glutamylarginine is a dipeptide composed of glutamate and arginine, and is a proteolytic breakdown product of larger proteins. It belongs to the family of N-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom. Glutamylarginine is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

Arginylglutamic acid

(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]pentanedioic acid

C11H21N5O5 (303.1543)


Arginylglutamic acid is a dipeptide composed of arginine and glutamic acid. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

Pimelylcarnitine

(3R)-3-[(6-carboxyhexanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C14H25NO6 (303.1682)


Pimelylcarnitine is an acylcarnitine. More specifically, it is an pimelic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Pimelylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine pimelylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-hydroxyoctanoyl carnitine

3-[(3-hydroxyoctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H29NO5 (303.2046)


3-Hydroxyoctanoyl carnitine is an acylcarnitine. More specifically, it is a 3-hydroxyoctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxyoctanoyl carnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxyoctanoyl carnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2,2-dimethylpentanedioylcarnitine

3-[(4-carboxy-4,4-dimethylbutanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C14H25NO6 (303.1682)


2,2-dimethylpentanedioylcarnitine is an acylcarnitine. More specifically, it is an 2,2-dimethylpentanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2,2-dimethylpentanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2,2-dimethylpentanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxyoctanoylcarnitine

3-[(5-hydroxyoctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H29NO5 (303.2046)


5-Hydroxyoctanoylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxyoctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxyoctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxyoctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Hydroxyoctanoylcarnitine

3-[(7-hydroxyoctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H29NO5 (303.2046)


7-Hydroxyoctanoylcarnitine is an acylcarnitine. More specifically, it is an 7-hydroxyoctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Hydroxyoctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-Hydroxyoctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Hydroxyoctanoylcarnitine

3-[(6-hydroxyoctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H29NO5 (303.2046)


6-hydroxyoctanoylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxyoctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-hydroxyoctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-hydroxyoctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Hydroxyoctanoylcarnitine

3-[(4-Hydroxyoctanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C15H29NO5 (303.2046)


4-hydroxyoctanoylcarnitine is an acylcarnitine. More specifically, it is an 4-hydroxyoctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-hydroxyoctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-hydroxyoctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxy-2-propylpentanoylcarnitine

3-[(5-hydroxy-2-propylpentanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H29NO5 (303.2046)


5-Hydroxy-2-propylpentanoylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxy-2-propylpentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxy-2-propylpentanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxy-2-propylpentanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-v-2-propylpentanoylcarnitine

3-[(3-hydroxy-2-propylpentanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H29NO5 (303.2046)


3-Hydroxy-2-propylpentanoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxy-2-propylpentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxy-2-propylpentanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxy-2-propylpentanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Hydroxy-2-propylpentanoylcarnitine

3-[(4-hydroxy-2-propylpentanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H29NO5 (303.2046)


4-Hydroxy-2-propylpentanoylcarnitine is an acylcarnitine. More specifically, it is an 4-hydroxy-2-propylpentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Hydroxy-2-propylpentanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Hydroxy-2-propylpentanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Ethylpentanedioylcarnitine

3-[(4-carboxy-4-ethylbutanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C14H25NO6 (303.1682)


2-Ethylpentanedioylcarnitine is an acylcarnitine. More specifically, it is an 2-ethylpentanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Ethylpentanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-Ethylpentanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Lauroyl Cysteine

2-dodecanamido-3-sulfanylpropanoic acid

C15H29NO3S (303.1868)


N-lauroyl cysteine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Lauric acid amide of Cysteine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Lauroyl Cysteine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Lauroyl Cysteine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

O-Pimeloylcarnitine

4-[(6-Carboxyhexanoyl)oxy]-4-(trimethylammonio)butanoic acid

C14H25NO6 (303.1682)


   

Aditoprim

5-{[4-(dimethylamino)-3,5-dimethoxyphenyl]methyl}pyrimidine-2,4-diamine

C15H21N5O2 (303.1695)


   

Aptiganel

N-(3-ethylphenyl)-N-methyl-N-(naphthalen-1-yl)guanidine

C20H21N3 (303.1735)


D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C26170 - Protective Agent > C1509 - Neuroprotective Agent D020011 - Protective Agents

   

Bornaprolol

1-(2-exo-Bicyclo(2,2,1)hept-2-ylphenoxy)-3- ((1-methylethyl)amino)-2-propanol

C19H29NO2 (303.2198)


   

1-Oxononan-4-yl (2R)-2-acetamido-3-sulfanylpropanoate

N-{1-oxo-1-[(1-oxononan-4-yl)oxy]-3-sulphanylpropan-2-yl}ethanimidic acid

C14H25NO4S (303.1504)


   

(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl) 3-methoxy-2-phenylpropanoate

(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl) 3-methoxy-2-phenylpropanoic acid

C18H25NO3 (303.1834)


   

Zolmitriptan N-Oxide

N,N-dimethyl-2-{5-[(2-oxo-1,3-oxazolidin-4-yl)methyl]-1H-indol-3-yl}ethanamine oxide

C16H21N3O3 (303.1583)


   

1-[(5-Methoxy-2,3-dihydro-1H-indol-3-yl)methylideneamino]-2-pentylguanidine

N-{[(5-methoxy-2,3-dihydro-1H-indol-3-yl)methylidene]amino}-N-pentylguanidine

C16H25N5O (303.2059)


   

N2-gamma-L-Glutamyl-L-arginine

2-amino-4-[(4-carbamimidamido-1-carboxybutyl)carbamoyl]butanoic acid

C11H21N5O5 (303.1543)


Constituent of Allium cepa (onion), Panax ginseng (ginseng). After intravenous administration of DTIC-Dome, the volume of distribution exceeds total body water content suggesting localization in some body tissue, probably the liver. Its disappearance from the plasma is biphasic with initial half-life of 19 minutes and a terminal half-life of 5 hours. 1 In a patient with renal and hepatic dysfunctions, the half-lives were lengthened to 55 minutes and 7.2 hours. 1 The average cumulative excretion of unchanged DTIC in the urine is 40\\% of the injected dose in 6 hours. 1 DTIC is subject to renal tubular secretion rather than glomerular filtration. At therapeutic concentrations DTIC is not appreciably bound to human plasma protein. N2-gamma-L-Glutamyl-L-arginine is found in garden onion, tea, and onion-family vegetables. Constituent of Allium cepa (onion), Panax ginseng (ginseng)

   

Acetylacrifoline

Acetylacrifoline

C18H25NO3 (303.1834)


   
   

Berkeleyamide A

Berkeleyamide A

C18H25NO3 (303.1834)


   

10-O-Demethylprotoemetine

10-O-Demethylprotoemetine

C18H25NO3 (303.1834)


   

9-O-Demethylprotoemetine

9-O-Demethylprotoemetine

C18H25NO3 (303.1834)


   

4-Methoxy-alpha-pop

4-Methoxy-alpha-pop

C19H29NO2 (303.2198)


   

3,4-Methylenedioxy PV8

3,4-Methylenedioxy PV8

C18H25NO3 (303.1834)


   

(+-)-N-Methyloreolin|(??)-Oridine|N-Methyl-oreolin|N-Methyl-oridin|N-Methyloreolin

(+-)-N-Methyloreolin|(??)-Oridine|N-Methyl-oreolin|N-Methyl-oridin|N-Methyloreolin

C18H25NO3 (303.1834)


   

dehydronitramidine

dehydronitramidine

C20H21N3 (303.1735)


   

Schoberidine

Schoberidine

C20H21N3 (303.1735)


   

10-Phenyl-8-propyllobeliolone|8-Propyl-10-phenyl-lobeliolon

10-Phenyl-8-propyllobeliolone|8-Propyl-10-phenyl-lobeliolon

C19H29NO2 (303.2198)


   

Cycloneosamandion

Cycloneosamandion

C19H29NO2 (303.2198)


   

(+)-mostueine|Mostueine.|mostuenine

(+)-mostueine|Mostueine.|mostuenine

C20H21N3 (303.1735)


   

(2R,2S)-3-(2,3-Dihydroxy-3-methylbutyl)-5-(2,3-epoxy-3-methylbutyl)indole

(2R,2S)-3-(2,3-Dihydroxy-3-methylbutyl)-5-(2,3-epoxy-3-methylbutyl)indole

C18H25NO3 (303.1834)


   
   

(E)-N-methyl-N-(1-naphthylmethyl)-3-(4-hydroxyphenyl)-2-propen-1-amine

(E)-N-methyl-N-(1-naphthylmethyl)-3-(4-hydroxyphenyl)-2-propen-1-amine

C21H21NO (303.1623)


   

(-)-suaveoline|(6S,13S)-4-ethyl-6,7,12,13-tetrahydro-7-methyl-6,13-imino-5H-pyrido[3,4:5,6]cyclooct[1,2-b]indole|4-ethyl-7-methyl-6,7,12,13-tetrahydro-5H-6,13-epiazano-pyrido[3,4:5,6]cycloocta[1,2-b]indole|Suaveolin|suaveoline|Suaveoline +

(-)-suaveoline|(6S,13S)-4-ethyl-6,7,12,13-tetrahydro-7-methyl-6,13-imino-5H-pyrido[3,4:5,6]cyclooct[1,2-b]indole|4-ethyl-7-methyl-6,7,12,13-tetrahydro-5H-6,13-epiazano-pyrido[3,4:5,6]cycloocta[1,2-b]indole|Suaveolin|suaveoline|Suaveoline +

C20H21N3 (303.1735)


   

(-)-berkeleyamide A|(10S,11R,14S)-berkeleyamide A|berkeleyamide A

(-)-berkeleyamide A|(10S,11R,14S)-berkeleyamide A|berkeleyamide A

C18H25NO3 (303.1834)


   

2-[(3-isopropoy-O-beta-D-glucopyranosyl)oxy]-2-methylbutanenitrile

2-[(3-isopropoy-O-beta-D-glucopyranosyl)oxy]-2-methylbutanenitrile

C14H25NO6 (303.1682)


   
   
   

(-)-3-methoxy-4-O-methyljoubertiamine|(S)-3-Methoxy-4-O-methyljoubertiamine|O-methyljoubertiamine

(-)-3-methoxy-4-O-methyljoubertiamine|(S)-3-Methoxy-4-O-methyljoubertiamine|O-methyljoubertiamine

C18H25NO3 (303.1834)


   

Oxine-3beta-3-Hydroxyandrost-5-en-17-one

Oxine-3beta-3-Hydroxyandrost-5-en-17-one

C19H29NO2 (303.2198)


   

(2E)-N-isobutyl-7-(3,4-methylenedioxy)phenylheptenenamide|(2E)-N-isobutyl-7-(3,4-methylenedioxyphenyl)hepta-2-enamide|Pipercallosidine

(2E)-N-isobutyl-7-(3,4-methylenedioxy)phenylheptenenamide|(2E)-N-isobutyl-7-(3,4-methylenedioxyphenyl)hepta-2-enamide|Pipercallosidine

C18H25NO3 (303.1834)


   

10-O-demethylproemethine|10-O-demethylprotoemetine

10-O-demethylproemethine|10-O-demethylprotoemetine

C18H25NO3 (303.1834)


   

3-hydroxy-3-nonyl-1H-quinoline-2,4-dione

3-hydroxy-3-nonyl-1H-quinoline-2,4-dione

C18H25NO3 (303.1834)


   

4-hydroxy-6-[(E,E)-3,7-dimethylocta-2,5-dienyl]-3-methyl-5-propyl-1H-pyridin-2-one|iromycin A|NK26588

4-hydroxy-6-[(E,E)-3,7-dimethylocta-2,5-dienyl]-3-methyl-5-propyl-1H-pyridin-2-one|iromycin A|NK26588

C19H29NO2 (303.2198)


   

(E)-N-methyl-N-(1-naphthylmethyl)-3-(3-hydroxyphenyl)-2-propen-1-amine

(E)-N-methyl-N-(1-naphthylmethyl)-3-(3-hydroxyphenyl)-2-propen-1-amine

C21H21NO (303.1623)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

Tribenzylamine N-oxide

Tribenzylamine N-oxide

C21H21NO (303.1623)


   
   
   

Vildagliptin

(2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]-1-oxoethyl]-2-pyrrolidinecarbonitrile

C17H25N3O2 (303.1947)


A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor CONFIDENCE standard compound; INTERNAL_ID 2266 INTERNAL_ID 2266; CONFIDENCE standard compound CONFIDENCE standard compound; EAWAG_UCHEM_ID 3146 Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1].

   

Vildagliptin (LAF-237)

Vildagliptin (LAF-237)

C17H25N3O2 (303.1947)


   

Antibiotic TAN 1169A

Antibiotic TAN 1169A

C16H21N3O3 (303.1583)


   

C18H25NO3_2-Heptenamide, 7-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)-, (2E)

NCGC00347573-02_C18H25NO3_2-Heptenamide, 7-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)-, (2E)-

C18H25NO3 (303.1834)


   

tetra(methoxymethyl)melamine (putative)

tetra(methoxymethyl)melamine (putative)

[C11H23N6O4]+ (303.1781)


   
   
   
   
   

1-Pyrrolidinepropanol, a-(4-hydroxycyclohexyl)-a-phenyl-, trans-

1-Pyrrolidinepropanol, a-(4-hydroxycyclohexyl)-a-phenyl-, trans-

C19H29NO2 (303.2198)


   

1-Pyrrolidinepropanol, a-(4-hydroxycyclohexyl)-a-phenyl-, cis-

1-Pyrrolidinepropanol, a-(4-hydroxycyclohexyl)-a-phenyl-, cis-

C19H29NO2 (303.2198)


   
   
   
   

Val Trp

Dipeptide-2

C16H21N3O3 (303.1583)


Dipeptide 2 (N-Valyltryptophan; Val-Trp) is a bioactive peptide with anti-aging effect and has been reported used as a cosmetic ingredient[1].

   
   
   
   

Atropine Methyl

Atropine Methyl

C18H25NO3 (303.1834)


   

(-)-Samandarone

(-)-Samandarone

C19H29NO2 (303.2198)


   

Cycloneosamadione

Cycloneosamadione

C19H29NO2 (303.2198)


   

1-O-Desmethyltetrabenazine

1-O-Desmethyltetrabenazine

C18H25NO3 (303.1834)


   

TRP-Val

2-(2-amino-3-methylbutanamido)-3-(1H-indol-3-yl)propanoic acid

C16H21N3O3 (303.1583)


A dipeptide formed from L-tryptophan and L-valine residues.

   

Val-TRP

2-[2-amino-3-(1H-indol-3-yl)propanamido]-3-methylbutanoic acid

C16H21N3O3 (303.1583)


C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor Dipeptide 2 (N-Valyltryptophan; Val-Trp) is a bioactive peptide with anti-aging effect and has been reported used as a cosmetic ingredient[1].

   

CAR 8:0;O

3S-{[-3-hydroxyoctanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C15H29NO5 (303.2046)


   

4-(1,1-Dimethylethyl)phenyl 1-(aminoiminomethyl)-4-piperidinecarboxyla te

4-(1,1-Dimethylethyl)phenyl 1-(aminoiminomethyl)-4-piperidinecarboxyla te

C17H25N3O2 (303.1947)


   

TERT-BUTYL 2-((TERT-BUTOXYCARBONYL)AMINO)-6-HYDROXYHEXANOATE

TERT-BUTYL 2-((TERT-BUTOXYCARBONYL)AMINO)-6-HYDROXYHEXANOATE

C15H29NO5 (303.2046)


   

Auramine O

Auramine O

C17H22ClN3 (303.1502)


D000890 - Anti-Infective Agents D004396 - Coloring Agents D004202 - Disinfectants

   

(2E)-N-(2,4-DIMETHYLPHENYL)-2-(HYDROXYIMINO)ACETAMIDE

(2E)-N-(2,4-DIMETHYLPHENYL)-2-(HYDROXYIMINO)ACETAMIDE

C21H21NO (303.1623)


   

(R)-2-AMINO-1,1,3-TRIPHENYLPROPAN-1-OL

(R)-2-AMINO-1,1,3-TRIPHENYLPROPAN-1-OL

C21H21NO (303.1623)


   

4-(trans-4-Propylcyclohexyl)-[1,1-biphenyl]-4-carbonitrile

4-(trans-4-Propylcyclohexyl)-[1,1-biphenyl]-4-carbonitrile

C22H25N (303.1987)


   

Boc-D-Glu(OtBu)-OH

Boc-D-Glu(OtBu)-OH

C14H25NO6 (303.1682)


   
   

benzyl 3-[3-(aminomethyl)azetidin-1-yl]piperidine-1-carboxylate

benzyl 3-[3-(aminomethyl)azetidin-1-yl]piperidine-1-carboxylate

C17H25N3O2 (303.1947)


   
   

2-(Tert-butylcarbonylamino)phenylboronic acid pinacol ester

2-(Tert-butylcarbonylamino)phenylboronic acid pinacol ester

C17H26BNO3 (303.2006)


   

4-(dipentylamino)-2-nitrobenzonitrile

4-(dipentylamino)-2-nitrobenzonitrile

C17H25N3O2 (303.1947)


   

1-METHYL-4-(6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-YL)PIPERAZINE

1-METHYL-4-(6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-YL)PIPERAZINE

C16H26BN3O2 (303.2118)


   

N-(PIPERIDIN-1-YL)-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-AMINE

N-(PIPERIDIN-1-YL)-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-AMINE

C16H26BN3O2 (303.2118)


   

2-piperazin-1-yl-4,6-dipyrrolidin-1-yl-1,3,5-triazine

2-piperazin-1-yl-4,6-dipyrrolidin-1-yl-1,3,5-triazine

C15H25N7 (303.2171)


   

3-azido-2 3-dideoxy-1-o-(t-butyldimethy&

3-azido-2 3-dideoxy-1-o-(t-butyldimethy&

C12H25N3O4Si (303.1614)


   
   

1-METHYL-4-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-YL)PIPERAZINE

1-METHYL-4-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-YL)PIPERAZINE

C16H26BN3O2 (303.2118)


   

4-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine

4-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine

C17H26BNO3 (303.2006)


   

4-(2-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL)MORPHOLINE

4-(2-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL)MORPHOLINE

C17H26BNO3 (303.2006)


   

TERT-BUTYL SPIRO[ISOCHROMAN-1,4-PIPERIDINE]-1-CARBOXYLATE

TERT-BUTYL SPIRO[ISOCHROMAN-1,4-PIPERIDINE]-1-CARBOXYLATE

C18H25NO3 (303.1834)


   

2,4-bis[(4-aminophenyl)methyl]aniline

2,4-bis[(4-aminophenyl)methyl]aniline

C20H21N3 (303.1735)


   

tert-Butyl 3-hydroxyspiro[indan-1,4-piperidine]-1-carboxylate

tert-Butyl 3-hydroxyspiro[indan-1,4-piperidine]-1-carboxylate

C18H25NO3 (303.1834)


   

4-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine

4-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine

C17H26BNO3 (303.2006)


   

N,N-diethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

N,N-diethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

C17H26BNO3 (303.2006)


   

N,N-Dibenzyl-p-anisidine

N,N-Dibenzyl-p-anisidine

C21H21NO (303.1623)


   

N-Methyl-3-pyrrolidinyl Cyclopentylmandelate

N-Methyl-3-pyrrolidinyl Cyclopentylmandelate

C18H25NO3 (303.1834)


   

N-CYCLOHEXYL-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIMIDIN-2-AMINE

N-CYCLOHEXYL-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIMIDIN-2-AMINE

C16H26BN3O2 (303.2118)


   

N-Isopropyl-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

N-Isopropyl-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

C17H26BNO3 (303.2006)


   

N-propyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide

N-propyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide

C17H26BNO3 (303.2006)


   

N-Isopropyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

N-Isopropyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

C17H26BNO3 (303.2006)


   

N-propyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide

N-propyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide

C17H26BNO3 (303.2006)


   

1-[3-(4-TERT-BUTYLBENZOYL)-PROPYL]-4-HYDROXYPIPERIDINE

1-[3-(4-TERT-BUTYLBENZOYL)-PROPYL]-4-HYDROXYPIPERIDINE

C19H29NO2 (303.2198)


   

Boc-Glu(OtBu)-OH

Boc-Glu(OtBu)-OH

C14H25NO6 (303.1682)


   
   

2-((4-Phenylpiperazine-1-yl)methyl)quinoline

2-((4-Phenylpiperazine-1-yl)methyl)quinoline

C20H21N3 (303.1735)


   

n-t-butyl-3-(4-(p-methoxyphenyl)piperazinyl)azetidine

n-t-butyl-3-(4-(p-methoxyphenyl)piperazinyl)azetidine

C18H29N3O (303.2311)


   

L-Arginine-L-pyroglutamate

L-Arginine-L-pyroglutamate

C11H21N5O5 (303.1543)


   

tert-Butyl 4-(4-methylbenzoyl)piperidine-1-carboxylate

tert-Butyl 4-(4-methylbenzoyl)piperidine-1-carboxylate

C18H25NO3 (303.1834)


   

tert-Butyl 4-(5H-pyrrolo[3,2-d]pyrimidin-4-yl)piperazine-1-carboxylate

tert-Butyl 4-(5H-pyrrolo[3,2-d]pyrimidin-4-yl)piperazine-1-carboxylate

C15H21N5O2 (303.1695)


   

Butoxamine hydrochloride

Butoxamine hydrochloride

C15H26ClNO3 (303.1601)


Butaxamine (Butoxamin) hydrochloride is a specific β2-adrenergic receptor blocker. Butaxamine hydrochloride inhibits the decreases in urine volume in ethanol-anesthetized, water-diuretic rats[1].

   

Methyl (8-benzyl-1-oxa-8-azaspiro[4.5]dec-2-yl)acetate

Methyl (8-benzyl-1-oxa-8-azaspiro[4.5]dec-2-yl)acetate

C18H25NO3 (303.1834)


   

(bis-tert-butoxycarbonylmethyl-amino)-acetic acid

(bis-tert-butoxycarbonylmethyl-amino)-acetic acid

C14H25NO6 (303.1682)


   

(2S)-2-Amino-1,1,3-triphenyl-1-propanol

(2S)-2-Amino-1,1,3-triphenyl-1-propanol

C21H21NO (303.1623)


   

BENZYL-(4-BENZYLOXYBENZYL)AMINE

BENZYL-(4-BENZYLOXYBENZYL)AMINE

C21H21NO (303.1623)


   

DI-TERT-BUTYL(NEOPENTYL)PHOSPHONIUM TETRAFLUOROBORATE

DI-TERT-BUTYL(NEOPENTYL)PHOSPHONIUM TETRAFLUOROBORATE

C13H29BF4P (303.2036)


   

7-((1-METHYLPIPERIDIN-4-YL)METHOXY)-6-METHOXYQUINAZOLIN-4(3H)-ONE

7-((1-METHYLPIPERIDIN-4-YL)METHOXY)-6-METHOXYQUINAZOLIN-4(3H)-ONE

C16H21N3O3 (303.1583)


   

Benzyl 4-(2-oxoimidazolidin-1-yl)piperidine-1-carboxylate

Benzyl 4-(2-oxoimidazolidin-1-yl)piperidine-1-carboxylate

C16H21N3O3 (303.1583)


   

Boc-d-glu-otbu

Boc-d-glu-otbu

C14H25NO6 (303.1682)


   

1H-PYRROLO[2,3-B]PYRIDIN-5-AMINE, 2-METHYL-1-[TRIS(1-METHYLETHYL)SILYL]-

1H-PYRROLO[2,3-B]PYRIDIN-5-AMINE, 2-METHYL-1-[TRIS(1-METHYLETHYL)SILYL]-

C17H29N3Si (303.2131)


   

2-(CYCLOHEXYLOXY)-6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDINE

2-(CYCLOHEXYLOXY)-6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDINE

C17H26BNO3 (303.2006)


   

tert-butyl 4-(1,3-benzoxazol-2-yl)piperazine-1-carboxylate

tert-butyl 4-(1,3-benzoxazol-2-yl)piperazine-1-carboxylate

C16H21N3O3 (303.1583)


   

1-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)piperazine

1-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)piperazine

C16H26BN3O2 (303.2118)


   

3-(2,5-dimethylphenyl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]decan-2-one

3-(2,5-dimethylphenyl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]decan-2-one

C18H25NO3 (303.1834)


   

(2R)-1-[2-[(3-Hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)amino]acetyl]-2-pyrrolidinecarbonitrile

(2R)-1-[2-[(3-Hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)amino]acetyl]-2-pyrrolidinecarbonitrile

C17H25N3O2 (303.1947)


(2R)-Vildagliptin is the isomer of Vildagliptin (HY-14291), and can be used as an experimental control. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1].

   

(1S,2R)-n-benzyl-2-amino-1,2-diphenylethanol

(1S,2R)-n-benzyl-2-amino-1,2-diphenylethanol

C21H21NO (303.1623)


   

4-Hydroxyestrone-4-methyl ether

4-Hydroxyestrone-4-methyl ether

C19H21D3O3 (303.1914)


   

(3R,4S,5S)-4-(tert-butoxycarbonyl(Methyl)amino)-3-Methoxy-5-Methylheptanoic acid

(3R,4S,5S)-4-(tert-butoxycarbonyl(Methyl)amino)-3-Methoxy-5-Methylheptanoic acid

C15H29NO5 (303.2046)


   

Vildagliptin Impurity L

Vildagliptin Impurity L

C17H25N3O2 (303.1947)


   

4-[1-Methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]butanoic acid

4-[1-Methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]butanoic acid

C16H21N3O3 (303.1583)


   

Lithium triisopropyl 2-(5-methoxypyridyl)borate

Lithium triisopropyl 2-(5-methoxypyridyl)borate

C15H27BLiNO4 (303.2193)


   

1,7-Bis-Boc-1,4,7-triazaheptane

1,7-Bis-Boc-1,4,7-triazaheptane

C14H29N3O4 (303.2158)


   

3-(1,3-Dimethylbutylidene)Aminopropyl Triethoxysilane

3-(1,3-Dimethylbutylidene)Aminopropyl Triethoxysilane

C15H33NO3Si (303.223)


   

2-(4-Methyl-piperazin-1-yl)pyridine-5-boronic acid pinacol ester

2-(4-Methyl-piperazin-1-yl)pyridine-5-boronic acid pinacol ester

C16H26BN3O2 (303.2118)


   

benzyl N-[(1-piperidin-4-ylazetidin-3-yl)methyl]carbamate

benzyl N-[(1-piperidin-4-ylazetidin-3-yl)methyl]carbamate

C17H25N3O2 (303.1947)


   

N,N-diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

N,N-diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

C17H26BNO3 (303.2006)


   

Aditoprim

Aditoprime

C15H21N5O2 (303.1695)


C471 - Enzyme Inhibitor > C2153 - Dihydrofolate Reductase Inhibitor D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists C254 - Anti-Infective Agent > C52588 - Antibacterial Agent

   

2,6-DI-T-BUTYL-4-(METHACRYLOYLAMINOMETHYL) PHENOL

2,6-DI-T-BUTYL-4-(METHACRYLOYLAMINOMETHYL) PHENOL

C19H29NO2 (303.2198)


   

5-tert-Butyl-4-diethylaminomethyl-2-methyl-furan-3-carboxylic acid hydrochloride

5-tert-Butyl-4-diethylaminomethyl-2-methyl-furan-3-carboxylic acid hydrochloride

C15H26ClNO3 (303.1601)


   

PIROHEPTINE

PIROHEPTINE

C22H25N (303.1987)


C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent

   

2-Cyclohexyloxypyridine-3-boronic acid pinacol ester

2-Cyclohexyloxypyridine-3-boronic acid pinacol ester

C17H26BNO3 (303.2006)


   

butyl prop-2-enoate, prop-2-enamide, styrene

butyl prop-2-enoate, prop-2-enamide, styrene

C18H25NO3 (303.1834)


   

benzyl N-[(1-piperidin-3-ylazetidin-3-yl)methyl]carbamate

benzyl N-[(1-piperidin-3-ylazetidin-3-yl)methyl]carbamate

C17H25N3O2 (303.1947)


   

N,N-dimethyl-2-[5-[(2-oxo-1,3-oxazolidin-4-yl)methyl]-1H-indol-3-yl]ethanamine Oxide

N,N-dimethyl-2-[5-[(2-oxo-1,3-oxazolidin-4-yl)methyl]-1H-indol-3-yl]ethanamine Oxide

C16H21N3O3 (303.1583)


   

(1-Tert-butyl-5-phenyl-1h-pyrrol-3-yl)(phenyl)methanone

(1-Tert-butyl-5-phenyl-1h-pyrrol-3-yl)(phenyl)methanone

C21H21NO (303.1623)


   

(3Z,5Z)-3,5-bis[(4-methylphenyl)methylidene]piperidin-4-one

(3Z,5Z)-3,5-bis[(4-methylphenyl)methylidene]piperidin-4-one

C21H21NO (303.1623)


   

N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide

N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide

C17H25N3O2 (303.1947)


   

3-hydroxyoctanoyl carnitine

3-[(3-hydroxyoctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H29NO5 (303.2046)


3-Hydroxyoctanoyl carnitine is an acylcarnitine. More specifically, it is a 3-hydroxyoctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxyoctanoyl carnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxyoctanoyl carnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5Z,8Z,11Z,14Z)-Icosa-5,8,11,14-tetraenoate

(5Z,8Z,11Z,14Z)-Icosa-5,8,11,14-tetraenoate

C20H31O2- (303.2324)


   

N6-[(Indole-3-yl)acetyl]-L-lysine

N6-[(Indole-3-yl)acetyl]-L-lysine

C16H21N3O3 (303.1583)


   

n-Methyl-l-valyl-l-tryptophanol

n-Methyl-l-valyl-l-tryptophanol

C17H25N3O2 (303.1947)


   

kauralexin A1

kauralexin A1

C20H31O2- (303.2324)


   

(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C20H31O2- (303.2324)


   

2,2-Dimethyl-4-(1H-1,2,4-triazole-1-yl)-7-phenoxy-3-heptanol

2,2-Dimethyl-4-(1H-1,2,4-triazole-1-yl)-7-phenoxy-3-heptanol

C17H25N3O2 (303.1947)


   

(5Z,11Z,14Z,17Z)-icosa-5,11,14,17-tetraenoate

(5Z,11Z,14Z,17Z)-icosa-5,11,14,17-tetraenoate

C20H31O2- (303.2324)


   
   
   

Pimelylcarnitine

Pimelylcarnitine

C14H25NO6 (303.1682)


   

5-Hydroxyoctanoylcarnitine

5-Hydroxyoctanoylcarnitine

C15H29NO5 (303.2046)


   

7-Hydroxyoctanoylcarnitine

7-Hydroxyoctanoylcarnitine

C15H29NO5 (303.2046)


   

6-Hydroxyoctanoylcarnitine

6-Hydroxyoctanoylcarnitine

C15H29NO5 (303.2046)


   

4-Hydroxyoctanoylcarnitine

4-Hydroxyoctanoylcarnitine

C15H29NO5 (303.2046)


   

2-Ethylpentanedioylcarnitine

2-Ethylpentanedioylcarnitine

C14H25NO6 (303.1682)


   

2,2-dimethylpentanedioylcarnitine

2,2-dimethylpentanedioylcarnitine

C14H25NO6 (303.1682)


   

5-Hydroxy-2-propylpentanoylcarnitine

5-Hydroxy-2-propylpentanoylcarnitine

C15H29NO5 (303.2046)


   

4-Hydroxy-2-propylpentanoylcarnitine

4-Hydroxy-2-propylpentanoylcarnitine

C15H29NO5 (303.2046)


   

3-v-2-propylpentanoylcarnitine

3-v-2-propylpentanoylcarnitine

C15H29NO5 (303.2046)


   

1-[(5-Methoxy-2,3-dihydro-1H-indol-3-yl)methylideneamino]-2-pentylguanidine

1-[(5-Methoxy-2,3-dihydro-1H-indol-3-yl)methylideneamino]-2-pentylguanidine

C16H25N5O (303.2059)


   

1-Oxononan-4-yl (2R)-2-acetamido-3-sulfanylpropanoate

1-Oxononan-4-yl (2R)-2-acetamido-3-sulfanylpropanoate

C14H25NO4S (303.1504)


   

3-Methyladipoylcarnitine

3-Methyladipoylcarnitine

C14H25NO6 (303.1682)


   

Pipercallosidine

Pipercallosidine

C18H25NO3 (303.1834)


An enamide that is (2E)-N-isobutylhept-2-enamide which is substituted at position 7 by a 3,4-methylenedioxyphenyl group. A natural product found in Piper sarmentosum.

   

Leu-Thr-Ala

Leu-Thr-Ala

C13H25N3O5 (303.1794)


A tripeptide composed of L-leucine, L-threonine and L-alanine joined in sequence by peptide linkages.

   
   
   

(2E,6E,10E)-geranylgeranate

(2E,6E,10E)-geranylgeranate

C20H31O2- (303.2324)


A polyunsaturated fatty acid anion resulting from the removal of a proton from the carboxy group of (2E,6E,10E)-geranylgeranic acid; major species at pH 7.3.

   

5-(3-Methylbutyl)-5-(2-pyridin-4-ylethyl)-1,3-diazinane-2,4,6-trione

5-(3-Methylbutyl)-5-(2-pyridin-4-ylethyl)-1,3-diazinane-2,4,6-trione

C16H21N3O3 (303.1583)


   

O-pimelylcarnitine

O-pimelylcarnitine

C14H25NO6 (303.1682)


An O-acylcarnitine in which the acyl group specified is pimelyl.

   

3-(1-methyl-2-oxoimidazo[4,5-b]pyridin-3-yl)-N-propan-2-ylpyrrolidine-1-carboxamide

3-(1-methyl-2-oxoimidazo[4,5-b]pyridin-3-yl)-N-propan-2-ylpyrrolidine-1-carboxamide

C15H21N5O2 (303.1695)


   

(4S)-4-(6-carboxyhexanoyloxy)-4-(trimethylazaniumyl)butanoate

(4S)-4-(6-carboxyhexanoyloxy)-4-(trimethylazaniumyl)butanoate

C14H25NO6 (303.1682)


   
   
   
   

[(2R,3R,6S)-3-amino-6-[2-[4-(2-pyridinyl)-1-triazolyl]ethyl]-2-oxanyl]methanol

[(2R,3R,6S)-3-amino-6-[2-[4-(2-pyridinyl)-1-triazolyl]ethyl]-2-oxanyl]methanol

C15H21N5O2 (303.1695)


   

[(2R,3R,6R)-3-amino-6-[2-[4-(2-pyridinyl)-1-triazolyl]ethyl]-2-oxanyl]methanol

[(2R,3R,6R)-3-amino-6-[2-[4-(2-pyridinyl)-1-triazolyl]ethyl]-2-oxanyl]methanol

C15H21N5O2 (303.1695)


   

[(2R,3S,6S)-3-amino-6-[2-[4-(2-pyridinyl)-1-triazolyl]ethyl]-2-oxanyl]methanol

[(2R,3S,6S)-3-amino-6-[2-[4-(2-pyridinyl)-1-triazolyl]ethyl]-2-oxanyl]methanol

C15H21N5O2 (303.1695)


   

[(2S,3S,6R)-3-amino-6-[2-[4-(2-pyridinyl)-1-triazolyl]ethyl]-2-oxanyl]methanol

[(2S,3S,6R)-3-amino-6-[2-[4-(2-pyridinyl)-1-triazolyl]ethyl]-2-oxanyl]methanol

C15H21N5O2 (303.1695)


   

Discadenine(1-)

Discadenine(1-)

C14H19N6O2- (303.1569)


An L-alpha-amino-acid anion that is the conjugate base formed when discadenine (a 6-isopentenylaminopurine having a 3-amino-3-carboxypropyl group attached at the 3-position) is deprotonated.

   
   
   
   
   
   
   
   
   
   

5-Nonyloxytryptaminium(1+)

5-Nonyloxytryptaminium(1+)

C19H31N2O+ (303.2436)


   

1-(2-amino-1-oxobutyl)-N-butyl-2,3-dihydroindole-2-carboxamide

1-(2-amino-1-oxobutyl)-N-butyl-2,3-dihydroindole-2-carboxamide

C17H25N3O2 (303.1947)


   

1-{(E)-2-(methylthio)-1-[2-(pentyloxy)phenyl]vinyl}-1H-imidazol-3-ium

1-{(E)-2-(methylthio)-1-[2-(pentyloxy)phenyl]vinyl}-1H-imidazol-3-ium

C17H23N2OS+ (303.1531)


   

9-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]nonanoate

9-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]nonanoate

C15H27O6- (303.1808)


   

(8R)-8-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]nonanoate

(8R)-8-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]nonanoate

C15H27O6- (303.1808)


   

2-amino-3-methyl-4H-imidazol-5-one;2-(6-methoxy-1H-indol-3-yl)ethanamine

2-amino-3-methyl-4H-imidazol-5-one;2-(6-methoxy-1H-indol-3-yl)ethanamine

C15H21N5O2 (303.1695)


   

tetra(methoxymethyl)melamine (putative)

tetra(methoxymethyl)melamine (putative)

C11H23N6O4+ (303.1781)


   

1-Butyl-5-hydroxy-3-methoxycarbonyl-2,4,6,7-tetramethylindole

1-Butyl-5-hydroxy-3-methoxycarbonyl-2,4,6,7-tetramethylindole

C18H25NO3 (303.1834)


   

2-(2-Hydroxyethoxy)-N-(2-(dimethylamino)ethyl)-4-qutnolinecarboxamide

2-(2-Hydroxyethoxy)-N-(2-(dimethylamino)ethyl)-4-qutnolinecarboxamide

C16H21N3O3 (303.1583)


   

N(6)-[(indol-3-yl)acetyl]-L-lysine

N(6)-[(indol-3-yl)acetyl]-L-lysine

C16H21N3O3 (303.1583)


D006133 - Growth Substances > D010937 - Plant Growth Regulators > D007210 - Indoleacetic Acids

   

Arachidonate

Arachidonate

C20H31O2 (303.2324)


A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.

   

Aptiganel

Aptiganel

C20H21N3 (303.1735)


D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C26170 - Protective Agent > C1509 - Neuroprotective Agent D020011 - Protective Agents

   

gamma-Glutamylarginine

gamma-Glutamylarginine

C11H21N5O5 (303.1543)


   

O-pimelyl-L-carnitine

O-pimelyl-L-carnitine

C14H25NO6 (303.1682)


An O-acyl-L-carnitine that is L-carnitine having a pimelyl group as the acyl substituent.

   

Glutamylarginine

Glutamylarginine

C11H21N5O5 (303.1543)


   

O-Pimeloylcarnitine

O-Pimeloylcarnitine

C14H25NO6 (303.1682)


An O-acylcarnitine having pimeloyl as the acyl substituent.

   

3-Hydroxyoctanoylcarnitine

3-Hydroxyoctanoylcarnitine

C15H29NO5 (303.2046)


An O-acylcarnitine having 3-hydroxyoctanoyl as the acyl substituent.

   

oscr#10(1-)

oscr#10(1-)

C15H27O6 (303.1808)


A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#10, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

ascr#10(1-)

ascr#10(1-)

C15H27O6 (303.1808)


A monocarboxylic acid anion resulting from the deprotonation of the carboxy group of ascr#10. The conjugate base of ascr#10 and the major species at pH 7.3.

   

icosatetraenoate

icosatetraenoate

C20H31O2 (303.2324)


A polyunsaturated fatty acid anion that is the conjugate base of icosatetraenoic acid, obtained by deprotonation of the carboxy group. Major species at pH 7.3.

   

N(6)-[(indol-3-yl)acetyl]-L-lysine zwitterion

N(6)-[(indol-3-yl)acetyl]-L-lysine zwitterion

C16H21N3O3 (303.1583)


Zwitterionic form of N(6)-[(indol-3-yl)acetyl]-L-lysine arising from transfer of a proton from the carboxy to the amino group; major species at pH 7.3.

   

all-cis-8,11,14,17-icosatetraenoate

all-cis-8,11,14,17-icosatetraenoate

C20H31O2 (303.2324)


An unsaturated fatty acid anion that is the conjugate base of all-cis-8,11,14,17-icosatetraenoic acid, obtained by deprotonation of the carboxy group.

   

(5Z,11Z,14Z,17Z)-icosatetraenoate

(5Z,11Z,14Z,17Z)-icosatetraenoate

C20H31O2 (303.2324)


An icosatetraenoate that is the conjugate base of (5Z,11Z,14Z,17Z)-icosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   
   
   
   
   

N(6)-[(Indol-3-yl)acetyl]-lysine

N(6)-[(Indol-3-yl)acetyl]-lysine

C16H21N3O3 (303.1583)


   
   

2-amino-4-[(4-carbamimidamido-1-carboxybutyl)-c-hydroxycarbonimidoyl]butanoic acid

2-amino-4-[(4-carbamimidamido-1-carboxybutyl)-c-hydroxycarbonimidoyl]butanoic acid

C11H21N5O5 (303.1543)


   

1-[(2r,6r)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]pentan-2-one

1-[(2r,6r)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]pentan-2-one

C19H29NO2 (303.2198)


   

n-{3-[(2s,5s)-5-benzyl-3,6-dihydroxy-2,5-dihydropyrazin-2-yl]propyl}guanidine

n-{3-[(2s,5s)-5-benzyl-3,6-dihydroxy-2,5-dihydropyrazin-2-yl]propyl}guanidine

C15H21N5O2 (303.1695)


   

17-ethyl-3-methyl-3,15,20-triazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8,13(18),14,16-heptaene

17-ethyl-3-methyl-3,15,20-triazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8,13(18),14,16-heptaene

C20H21N3 (303.1735)


   

(2s)-2-amino-6-{[1-hydroxy-2-(1h-indol-3-yl)ethylidene]amino}hexanoic acid

(2s)-2-amino-6-{[1-hydroxy-2-(1h-indol-3-yl)ethylidene]amino}hexanoic acid

C16H21N3O3 (303.1583)


   

(2s)-2-{[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-isopropoxyoxan-2-yl]oxy}-2-methylbutanenitrile

(2s)-2-{[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-isopropoxyoxan-2-yl]oxy}-2-methylbutanenitrile

C14H25NO6 (303.1682)


   

(1s,15r,16r,21s)-4,14,20-triazahexacyclo[13.6.2.0²,¹⁴.0³,¹¹.0⁵,¹⁰.0¹⁶,²¹]tricosa-2,4,6,8,10,12-hexaene

(1s,15r,16r,21s)-4,14,20-triazahexacyclo[13.6.2.0²,¹⁴.0³,¹¹.0⁵,¹⁰.0¹⁶,²¹]tricosa-2,4,6,8,10,12-hexaene

C20H21N3 (303.1735)


   

1-{5-[(3,3-dimethyloxiran-2-yl)methyl]-1h-indol-3-yl}-3-methylbutane-2,3-diol

1-{5-[(3,3-dimethyloxiran-2-yl)methyl]-1h-indol-3-yl}-3-methylbutane-2,3-diol

C18H25NO3 (303.1834)


   

2-{[3,5-dihydroxy-6-(hydroxymethyl)-4-isopropoxyoxan-2-yl]oxy}-2-methylbutanenitrile

2-{[3,5-dihydroxy-6-(hydroxymethyl)-4-isopropoxyoxan-2-yl]oxy}-2-methylbutanenitrile

C14H25NO6 (303.1682)


   

(2s,11bs)-2-[(2r)-1-hydroxybut-3-en-2-yl]-9-methoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-10-ol

(2s,11bs)-2-[(2r)-1-hydroxybut-3-en-2-yl]-9-methoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-10-ol

C18H25NO3 (303.1834)


   

(2s,11bs)-2-[(2s)-1-hydroxybut-3-en-2-yl]-9-methoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-10-ol

(2s,11bs)-2-[(2s)-1-hydroxybut-3-en-2-yl]-9-methoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-10-ol

C18H25NO3 (303.1834)


   

(2s)-2-{[(4s)-4-amino-4-carboxy-1-hydroxybutylidene]amino}-5-carbamimidamidopentanoic acid

(2s)-2-{[(4s)-4-amino-4-carboxy-1-hydroxybutylidene]amino}-5-carbamimidamidopentanoic acid

C11H21N5O5 (303.1543)


   

(4s)-4-[(3r,5r)-5-[(2s)-butan-2-yl]-2-hydroxy-4,5-dihydro-3h-pyrrol-3-yl]-4-hydroxy-1-phenylbutan-2-one

(4s)-4-[(3r,5r)-5-[(2s)-butan-2-yl]-2-hydroxy-4,5-dihydro-3h-pyrrol-3-yl]-4-hydroxy-1-phenylbutan-2-one

C18H25NO3 (303.1834)


   

(4s)-4-(3,4-dimethoxyphenyl)-4-[2-(dimethylamino)ethyl]cyclohex-2-en-1-one

(4s)-4-(3,4-dimethoxyphenyl)-4-[2-(dimethylamino)ethyl]cyclohex-2-en-1-one

C18H25NO3 (303.1834)


   

4,14,20-triazahexacyclo[13.6.2.0²,¹⁴.0³,¹¹.0⁵,¹⁰.0¹⁶,²¹]tricosa-2,4,6,8,10,20-hexaene

4,14,20-triazahexacyclo[13.6.2.0²,¹⁴.0³,¹¹.0⁵,¹⁰.0¹⁶,²¹]tricosa-2,4,6,8,10,20-hexaene

C20H21N3 (303.1735)


   

7-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)hept-2-enimidic acid

7-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)hept-2-enimidic acid

C18H25NO3 (303.1834)


   

(2r)-1-(5-{[(2s)-3,3-dimethyloxiran-2-yl]methyl}-1h-indol-3-yl)-3-methylbutane-2,3-diol

(2r)-1-(5-{[(2s)-3,3-dimethyloxiran-2-yl]methyl}-1h-indol-3-yl)-3-methylbutane-2,3-diol

C18H25NO3 (303.1834)


   

2-[(2r,3r,11bs)-3-ethyl-10-hydroxy-9-methoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl]acetaldehyde

2-[(2r,3r,11bs)-3-ethyl-10-hydroxy-9-methoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl]acetaldehyde

C18H25NO3 (303.1834)


   

6-[(2e,5e)-3,7-dimethylocta-2,5-dien-1-yl]-3-methyl-5-propylpyridine-2,4-diol

6-[(2e,5e)-3,7-dimethylocta-2,5-dien-1-yl]-3-methyl-5-propylpyridine-2,4-diol

C19H29NO2 (303.2198)


   

(2e)-4-[(1s,3r,4s,7s)-4-hexyl-2-oxa-6-azatricyclo[5.3.0.0¹,³]dec-8-en-10-ylidene]but-2-enoic acid

(2e)-4-[(1s,3r,4s,7s)-4-hexyl-2-oxa-6-azatricyclo[5.3.0.0¹,³]dec-8-en-10-ylidene]but-2-enoic acid

C18H25NO3 (303.1834)


   

(2e)-7-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)hept-2-enimidic acid

(2e)-7-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)hept-2-enimidic acid

C18H25NO3 (303.1834)


   

(4s)-4-hydroxy-4-[(3r,5s)-2-hydroxy-5-(2-methylpropyl)-4,5-dihydro-3h-pyrrol-3-yl]-1-phenylbutan-2-one

(4s)-4-hydroxy-4-[(3r,5s)-2-hydroxy-5-(2-methylpropyl)-4,5-dihydro-3h-pyrrol-3-yl]-1-phenylbutan-2-one

C18H25NO3 (303.1834)


   

2-(1-hydroxybut-3-en-2-yl)-9-methoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-10-ol

2-(1-hydroxybut-3-en-2-yl)-9-methoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-10-ol

C18H25NO3 (303.1834)


   

2-amino-6-{[1-hydroxy-2-(1h-indol-3-yl)ethylidene]amino}hexanoic acid

2-amino-6-{[1-hydroxy-2-(1h-indol-3-yl)ethylidene]amino}hexanoic acid

C16H21N3O3 (303.1583)


   

(1r,15r,16s)-4,14,20-triazahexacyclo[13.6.2.0²,¹⁴.0³,¹¹.0⁵,¹⁰.0¹⁶,²¹]tricosa-2,4,6,8,10,20-hexaene

(1r,15r,16s)-4,14,20-triazahexacyclo[13.6.2.0²,¹⁴.0³,¹¹.0⁵,¹⁰.0¹⁶,²¹]tricosa-2,4,6,8,10,20-hexaene

C20H21N3 (303.1735)


   

1-[6-(2-hydroxy-2-phenylethyl)-1-methylpiperidin-2-yl]pentan-2-one

1-[6-(2-hydroxy-2-phenylethyl)-1-methylpiperidin-2-yl]pentan-2-one

C19H29NO2 (303.2198)


   

6-(3,7-dimethylocta-2,5-dien-1-yl)-3-methyl-5-propylpyridine-2,4-diol

6-(3,7-dimethylocta-2,5-dien-1-yl)-3-methyl-5-propylpyridine-2,4-diol

C19H29NO2 (303.2198)


   

(1s,10s,11r,13s,15r)-15-methyl-14-oxo-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-yl acetate

(1s,10s,11r,13s,15r)-15-methyl-14-oxo-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-yl acetate

C18H25NO3 (303.1834)


   

4-(3,4-dimethoxyphenyl)-4-[2-(dimethylamino)ethyl]cyclohex-2-en-1-one

4-(3,4-dimethoxyphenyl)-4-[2-(dimethylamino)ethyl]cyclohex-2-en-1-one

C18H25NO3 (303.1834)


   

4-hydroxy-4-[2-hydroxy-5-(2-methylpropyl)-4,5-dihydro-3h-pyrrol-3-yl]-1-phenylbutan-2-one

4-hydroxy-4-[2-hydroxy-5-(2-methylpropyl)-4,5-dihydro-3h-pyrrol-3-yl]-1-phenylbutan-2-one

C18H25NO3 (303.1834)


   

2-{3-ethyl-10-hydroxy-9-methoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}acetaldehyde

2-{3-ethyl-10-hydroxy-9-methoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}acetaldehyde

C18H25NO3 (303.1834)


   

(2s)-2-{[(2s)-2-amino-1-hydroxy-3-methylbutylidene]amino}-3-(1h-indol-3-yl)propanoic acid

(2s)-2-{[(2s)-2-amino-1-hydroxy-3-methylbutylidene]amino}-3-(1h-indol-3-yl)propanoic acid

C16H21N3O3 (303.1583)